cobalt (Co)-supplementation of vitamin D3 (50,000 IU every 2 weeks) + 4-strain probiotic (L. acidophilus, B. bifidum, L. reuteri, L. fermentum; 8 x 10^9 CFU/day) for 12 weeks, adjunctive to antipsychotics. This is the strongest single-trial result for a microbiome-targeted intervention in schizophrenia, producing simultaneous psychiatric, inflammatory, oxidative, and metabolic improvement.
Evidence map1 cited passagesInspect provenance +
Source:
Evidence#
RCT (Ghaderi 2019)#
Design: Double-blind, placebo-controlled RCT, n=60 chronic schizophrenia patients, 12 weeks. Psychiatric outcomes: Total PANSS -7.4 vs -1.9 (p = 0.01); General PANSS -3.1 vs +0.3 (p = 0.004). Inflammatory markers: hs-CRP -2.3 vs -0.3 mg/L (p = 0.001).
Oxidative stress: Total antioxidant capacity +51.1 vs -20.7 mmol/L (p = 0.007); malondialdehyde significantly reduced (p = 0.01).
Metabolic markers: Fasting glucose -7.0 vs -0.2 mg/dL (p = 0.01); insulin -2.7 vs +0.4 microIU/mL (p < 0.001); HOMA-IR -0.8 vs +0.1 (p < 0.001); triglycerides and total cholesterol reduced.
Source:.[1]Clinical and Metabolic Response to Vitamin D Plus Probiotic in Schizophrenia PatientsGhaderi A, Banafshe HR, Mirhosseini N et al. · 2019Open reference 1 ↓
Mechanism#
Dual-action targeting two signature features simultaneously:
Vitamin D repletion: 85% of schizophrenia patients have suboptimal vitamin D levels—the lowest of any psychiatric condition. Vitamin D modulates Th17/Treg balance (skewed toward Th17 in schizophrenia), reduces IL-6 and TNF-alpha, and supports gut barrier integrity.
4-strain probiotic: The specific formulation (L. acidophilus, B. bifidum, L. reuteri, L. fermentum) restores microbial balance and reduces systemic inflammation. This is the same strain combination that consistently shows benefit in the Ye 2025 meta-analysis, in contrast to the failed L. rhamnosus GG + B. animalis Bb12 combination.
The combination addresses the schizophrenia signature at multiple levels: immune dysregulation (CRP, cytokines), oxidative burden (malondialdehyde, antioxidant capacity), metabolic syndrome (glucose, insulin, lipids), and gut-brain axis signaling.
Clinical Context#
The vitamin D + probiotic combination is notable for its favorable risk profile and low cost. The fact that 85% of schizophrenia patients are vitamin D deficient suggests this intervention corrects a near-universal nutritional deficit in this population while simultaneously addressing the microbiome signature.
The 4-strain probiotic formulation is the critical component—practitioners must use the validated strains, not generic probiotics (see STOP: Wrong-Strain Probiotics for Schizophrenia Psychiatric Symptoms).
References 2
Numbered by first appearance in the article, then reconciled with its declared source list.
- 1
Ghaderi A, Banafshe HR, Mirhosseini N et al. (2019). Clinical and Metabolic Response to Vitamin D Plus Probiotic in Schizophrenia Patients. BMC Psychiatry.
- 2
Juckel G, Freund N (2023). Microglia and Microbiome in Schizophrenia: Can Immunomodulation Improve Symptoms?. Journal of Neural Transmission.
Article network
Connect the evidence
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
No discussion yet. Start with a precise question or a source-backed observation.
Activity and accepted changes
Accepted researcher context, editorial status, public discussion, and upstream Git revisions are shown together. Pending, declined, and withdrawn proposals remain private.
- published revision
Deepen metal/concept entities + 8 new sources for T1D/schizophrenia
WikiBiome Deploy Bot · +60 −0
Inspect exact Git diff ↗